Cargando…

Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management

Hyperlipidemia is a crucial risk factor for the initiation and progression of atherosclerosis, ultimately leading to cardiovascular disease. The nanogel-based nanoplatform has emerged as an extremely promising drug delivery technology. Pravastatin Sodium (PS) is a cholesterol-lowering drug used to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraogi, Gaurav Kant, Tholiya, Siddharth, Mishra, Yachana, Mishra, Vijay, Albutti, Aqel, Nayak, Pallavi, Tambuwala, Murtaza M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871575/
https://www.ncbi.nlm.nih.gov/pubmed/35200462
http://dx.doi.org/10.3390/gels8020081
_version_ 1784657029177016320
author Saraogi, Gaurav Kant
Tholiya, Siddharth
Mishra, Yachana
Mishra, Vijay
Albutti, Aqel
Nayak, Pallavi
Tambuwala, Murtaza M.
author_facet Saraogi, Gaurav Kant
Tholiya, Siddharth
Mishra, Yachana
Mishra, Vijay
Albutti, Aqel
Nayak, Pallavi
Tambuwala, Murtaza M.
author_sort Saraogi, Gaurav Kant
collection PubMed
description Hyperlipidemia is a crucial risk factor for the initiation and progression of atherosclerosis, ultimately leading to cardiovascular disease. The nanogel-based nanoplatform has emerged as an extremely promising drug delivery technology. Pravastatin Sodium (PS) is a cholesterol-lowering drug used to treat hyperlipidemia. This study aimed to fabricate Pravastatin-loaded nanogel for evaluation of its effect in hyperlipidemia treatment. Pravastatin-loaded chitosan nanoparticles (PS-CS-NPs) were prepared by the ionic gelation method; then, these prepared NPs were converted to nanogel by adding a specified amount of 5% poloxamer solution. Various parameters, including drug entrapment efficacy, in vitro drug release, and hemolytic activity of the developed and optimized formulation, were evaluated. The in vitro drug release of the nanogel formulation revealed the sustained release (59.63% in 24 h) of the drug. The drug excipients compatibility studies revealed no interaction between the drug and the screened excipients. Higher drug entrapment efficacy was observed. The hemolytic activity showed lesser toxicity in nanoformulation than the pure drug solution. These findings support the prospective use of orally administered pravastatin-loaded nanogel as an effective and safe nano delivery system in hyperlipidemia treatment.
format Online
Article
Text
id pubmed-8871575
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88715752022-02-25 Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management Saraogi, Gaurav Kant Tholiya, Siddharth Mishra, Yachana Mishra, Vijay Albutti, Aqel Nayak, Pallavi Tambuwala, Murtaza M. Gels Article Hyperlipidemia is a crucial risk factor for the initiation and progression of atherosclerosis, ultimately leading to cardiovascular disease. The nanogel-based nanoplatform has emerged as an extremely promising drug delivery technology. Pravastatin Sodium (PS) is a cholesterol-lowering drug used to treat hyperlipidemia. This study aimed to fabricate Pravastatin-loaded nanogel for evaluation of its effect in hyperlipidemia treatment. Pravastatin-loaded chitosan nanoparticles (PS-CS-NPs) were prepared by the ionic gelation method; then, these prepared NPs were converted to nanogel by adding a specified amount of 5% poloxamer solution. Various parameters, including drug entrapment efficacy, in vitro drug release, and hemolytic activity of the developed and optimized formulation, were evaluated. The in vitro drug release of the nanogel formulation revealed the sustained release (59.63% in 24 h) of the drug. The drug excipients compatibility studies revealed no interaction between the drug and the screened excipients. Higher drug entrapment efficacy was observed. The hemolytic activity showed lesser toxicity in nanoformulation than the pure drug solution. These findings support the prospective use of orally administered pravastatin-loaded nanogel as an effective and safe nano delivery system in hyperlipidemia treatment. MDPI 2022-01-28 /pmc/articles/PMC8871575/ /pubmed/35200462 http://dx.doi.org/10.3390/gels8020081 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saraogi, Gaurav Kant
Tholiya, Siddharth
Mishra, Yachana
Mishra, Vijay
Albutti, Aqel
Nayak, Pallavi
Tambuwala, Murtaza M.
Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
title Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
title_full Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
title_fullStr Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
title_full_unstemmed Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
title_short Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
title_sort formulation development and evaluation of pravastatin-loaded nanogel for hyperlipidemia management
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871575/
https://www.ncbi.nlm.nih.gov/pubmed/35200462
http://dx.doi.org/10.3390/gels8020081
work_keys_str_mv AT saraogigauravkant formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement
AT tholiyasiddharth formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement
AT mishrayachana formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement
AT mishravijay formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement
AT albuttiaqel formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement
AT nayakpallavi formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement
AT tambuwalamurtazam formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement